{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T14:45:27Z","timestamp":1777733127160,"version":"3.51.4"},"reference-count":64,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:00:00Z","timestamp":1729814400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["F31HL166193"],"award-info":[{"award-number":["F31HL166193"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["2022"],"award-info":[{"award-number":["2022"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32GM135081"],"award-info":[{"award-number":["T32GM135081"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","cysticfibrosisjournal.com","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jcf.2024.10.008","type":"journal-article","created":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T17:34:25Z","timestamp":1731432865000},"page":"164-174","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["A W1282X cystic fibrosis mouse allows the study of pharmacological and gene-editing therapeutics to restore CFTR function"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2841-2966","authenticated-orcid":false,"given":"Margaret","family":"Michicich","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zachary","family":"Traylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caitlan","family":"McCoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana M.","family":"Valerio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alma","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4572-5266","authenticated-orcid":false,"given":"Molly","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4483-9876","authenticated-orcid":false,"given":"Sakeena","family":"Davis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4953-5458","authenticated-orcid":false,"given":"Amanda","family":"Barabas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4558-2947","authenticated-orcid":false,"given":"Rachel J.","family":"Mann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3820-0645","authenticated-orcid":false,"given":"David F.","family":"LePage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weihong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4739-5153","authenticated-orcid":false,"given":"Mitchell L.","family":"Drumm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas J.","family":"Kelley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8601-8129","authenticated-orcid":false,"given":"Ronald A.","family":"Conlon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig A.","family":"Hodges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.jcf.2024.10.008_bib0001","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.jcf.2024.10.008_bib0002","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jcf.2024.10.008_bib0003","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2024.10.008_bib0004","unstructured":"Cystic Fibrosis Mutation Database (CFTR1); available at http:\/\/www.genet.sickkids.on.ca\/cftr\/Home.html."},{"key":"10.1016\/j.jcf.2024.10.008_bib0005","unstructured":"The Clinical and Functional TRanslation of CFTR (CFTR2); available at http:\/cftr2.org."},{"issue":"11","key":"10.1016\/j.jcf.2024.10.008_bib0006","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1038\/s41588-019-0517-5","article-title":"The impact of nonsense-mediated mRNA decay on genetic disease, gene editing and cancer immunotherapy","volume":"51","author":"Lindeboom","year":"2019","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.jcf.2024.10.008_bib0007","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22010344","article-title":"Synergy between Readthrough and Nonsense Mediated Decay Inhibition in a Murine Model of Cystic Fibrosis Nonsense Mutations","volume":"22","author":"McHugh","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.jcf.2024.10.008_bib0008","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1165\/rcmb.2013-0282OC","article-title":"Synthetic aminoglycosides efficiently suppress cystic fibrosis transmembrane conductance regulator nonsense mutations and are enhanced by ivacaftor","volume":"50","author":"Xue","year":"2014","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"3","key":"10.1016\/j.jcf.2024.10.008_bib0009","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1172\/JCI28523","article-title":"Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin","volume":"117","author":"Linde","year":"2007","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.jcf.2024.10.008_bib0010","doi-asserted-by":"crossref","first-page":"e1641","DOI":"10.1002\/wrna.1641","article-title":"Therapeutic promise of engineered nonsense suppressor tRNAs","volume":"12","author":"Porter","year":"2021","journal-title":"Wiley Interdiscip Rev RNA"},{"issue":"2","key":"10.1016\/j.jcf.2024.10.008_bib0011","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.gendis.2018.11.005","article-title":"Delivering on the promise of gene editing for cystic fibrosis","volume":"6","author":"Hodges","year":"2019","journal-title":"Genes Dis"},{"issue":"6","key":"10.1016\/j.jcf.2024.10.008_bib0012","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.cell.2016.05.053","article-title":"Leveraging Rules of Nonsense-Mediated mRNA Decay for Genome Engineering and Personalized Medicine","volume":"165","author":"Popp","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.jcf.2024.10.008_bib0013","article-title":"To NMD or Not To NMD: Nonsense-Mediated mRNA Decay in Cancer and Other Genetic Diseases","author":"Supek","year":"2020","journal-title":"Trends Genet"},{"issue":"1","key":"10.1016\/j.jcf.2024.10.008_bib0014","first-page":"222","article-title":"Association of a nonsense mutation (W1282X), the most common mutation in the Ashkenazi Jewish cystic fibrosis patients in Israel, with presentation of severe disease","volume":"50","author":"Shoshani","year":"1992","journal-title":"Am J Hum Genet"},{"issue":"3","key":"10.1016\/j.jcf.2024.10.008_bib0015","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1074\/jbc.M116.764720","article-title":"Correctors and Potentiators Rescue Function of the Truncated W1282X-Cystic Fibrosis Transmembrane Regulator (CFTR) Translation Product","volume":"292","author":"Haggie","year":"2017","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.jcf.2024.10.008_bib0016","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0152232","article-title":"Robust Stimulation of W1282X-CFTR Channel Activity by a Combination of Allosteric Modulators","volume":"11","author":"Wang","year":"2016","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.jcf.2024.10.008_bib0017","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jcf.2019.02.009","article-title":"Decreased mRNA and protein stability of W1282X limits response to modulator therapy","volume":"18","author":"Aksit","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jcf.2024.10.008_bib0018","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1165\/rcmb.2018-0316OC","article-title":"Nonsense-mediated RNA Decay Pathway Inhibition Restores Expression and Function of W1282X CFTR","volume":"61","author":"Keenan","year":"2019","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"4","key":"10.1016\/j.jcf.2024.10.008_bib0019","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.jcf.2018.12.001","article-title":"Isogenic cell models of cystic fibrosis-causing variants in natively expressing pulmonary epithelial cells","volume":"18","author":"Valley","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.jcf.2024.10.008_bib0020","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.jcf.2019.12.001","article-title":"Functional rescue of c.3846G>A (W1282X) in patient-derived nasal cultures achieved by inhibition of nonsense mediated decay and protein modulators with complementary mechanisms of action","volume":"19","author":"Laselva","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jcf.2024.10.008_bib0021","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0199573","article-title":"A G542X cystic fibrosis mouse model for examining nonsense mutation directed therapies","volume":"13","author":"McHugh","year":"2018","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.jcf.2024.10.008_bib0022","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.ymthe.2023.01.014","article-title":"Use of 2,6-diaminopurine as a potent suppressor of UGA premature stop codons in cystic fibrosis","volume":"31","author":"Leroy","year":"2023","journal-title":"Mol Ther"},{"key":"10.1016\/j.jcf.2024.10.008_bib0023","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.921680","article-title":"Pharmacological Responses of the G542X-CFTR to CFTR Modulators","volume":"9","author":"Fang","year":"2022","journal-title":"Front Mol Biosci"},{"issue":"11","key":"10.1016\/j.jcf.2024.10.008_bib0024","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1007723","article-title":"Capitalizing on the heterogeneous effects of CFTR nonsense and frameshift variants to inform therapeutic strategy for cystic fibrosis","volume":"14","author":"Sharma","year":"2018","journal-title":"PLoS Genet"},{"issue":"10","key":"10.1016\/j.jcf.2024.10.008_bib0025","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1101\/gr.176701.114","article-title":"OutKnocker: a web tool for rapid and simple genotyping of designer nuclease edited cell lines","volume":"24","author":"Schmid-Burgk","year":"2014","journal-title":"Genome Res"},{"issue":"5","key":"10.1016\/j.jcf.2024.10.008_bib0026","doi-asserted-by":"crossref","first-page":"L1173","DOI":"10.1152\/ajplung.2001.281.5.L1173","article-title":"Examining basal chloride transport using the nasal potential difference response in a murine model","volume":"281","author":"Brady","year":"2001","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"10","key":"10.1016\/j.jcf.2024.10.008_bib0027","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/dvg.20433","article-title":"Generation of a conditional null allele for Cftr in mice","volume":"46","author":"Hodges","year":"2008","journal-title":"Genesis"},{"issue":"6","key":"10.1016\/j.jcf.2024.10.008_bib0028","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jcf.2016.06.005","article-title":"A novel guluronate oligomer improves intestinal transit and survival in cystic fibrosis mice","volume":"15","author":"Vitko","year":"2016","journal-title":"J Cyst Fibros"},{"issue":"7244","key":"10.1016\/j.jcf.2024.10.008_bib0029","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nature07935","article-title":"Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche","volume":"459","author":"Sato","year":"2009","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.jcf.2024.10.008_bib0030","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/nm.3201","article-title":"A functional CFTR assay using primary cystic fibrosis intestinal organoids","volume":"19","author":"Dekkers","year":"2013","journal-title":"Nat Med"},{"issue":"6235","key":"10.1016\/j.jcf.2024.10.008_bib0031","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1126\/science.1261877","article-title":"Human genomics. Effect of predicted protein-truncating genetic variants on the human transcriptome","volume":"348","author":"Rivas","year":"2015","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.jcf.2024.10.008_bib0032","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1073\/pnas.94.6.2604","article-title":"In vivo activation of the cystic fibrosis transmembrane conductance regulator mutant deltaF508 in murine nasal epithelium","volume":"94","author":"Kelley","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.jcf.2024.10.008_bib0033","doi-asserted-by":"crossref","first-page":"G528","DOI":"10.1152\/ajpgi.00052.2011","article-title":"Cystic fibrosis growth retardation is not correlated with loss of Cftr in the intestinal epithelium","volume":"301","author":"Hodges","year":"2011","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"120","key":"10.1016\/j.jcf.2024.10.008_bib0034","doi-asserted-by":"crossref","DOI":"10.3791\/55159-v","article-title":"Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients","author":"Boj","year":"2017","journal-title":"J Vis Exp"},{"issue":"344","key":"10.1016\/j.jcf.2024.10.008_bib0035","doi-asserted-by":"crossref","first-page":"344ra84","DOI":"10.1126\/scitranslmed.aad8278","article-title":"Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis","volume":"8","author":"Dekkers","year":"2016","journal-title":"Sci Transl Med"},{"issue":"3","key":"10.1016\/j.jcf.2024.10.008_bib0036","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1177\/2472630317692561","article-title":"High-Throughput Screening for Readthrough Modulators of CFTR PTC Mutations","volume":"22","author":"Liang","year":"2017","journal-title":"SLAS Technol"},{"issue":"7","key":"10.1016\/j.jcf.2024.10.008_bib0037","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1017\/S1355838200000716","article-title":"Aminoglycoside antibiotics mediate context-dependent suppression of termination codons in a mammalian translation system","volume":"6","author":"Manuvakhova","year":"2000","journal-title":"RNA"},{"issue":"3","key":"10.1016\/j.jcf.2024.10.008_bib0038","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jcf.2022.10.010","article-title":"The U UGA C sequence provides a favorable context to ELX-02 induced CFTR readthrough","volume":"22","author":"Pranke","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"21","key":"10.1016\/j.jcf.2024.10.008_bib0039","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222111972","article-title":"Comprehensive Analysis of Combinatorial Pharmacological Treatments to Correct Nonsense Mutations in the CFTR Gene","volume":"22","author":"Venturini","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.jcf.2024.10.008_bib0040","doi-asserted-by":"crossref","first-page":"729","DOI":"10.3892\/ijmm.2013.1601","article-title":"Comparison of read-through effects of aminoglycosides and PTC124 on rescuing nonsense mutations of HERG gene associated with long QT syndrome","volume":"33","author":"Yu","year":"2014","journal-title":"Int J Mol Med"},{"issue":"2","key":"10.1016\/j.jcf.2024.10.008_bib0041","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jcf.2021.09.020","article-title":"Functional Restoration of CFTR Nonsense Mutations in Intestinal Organoids","volume":"21","author":"de Poel","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2024.10.008_bib0042","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1038\/s41467-020-15140-z","article-title":"2,6-Diaminopurine as a highly potent corrector of UGA nonsense mutations","volume":"11","author":"Trzaska","year":"2020","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.jcf.2024.10.008_bib0043","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41556-020-0472-5","article-title":"Fast and efficient generation of knock-in human organoids using homology-independent CRISPR-Cas9 precision genome editing","volume":"22","author":"Artegiani","year":"2020","journal-title":"Nat Cell Biol"},{"issue":"6","key":"10.1016\/j.jcf.2024.10.008_bib0044","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.stem.2013.11.002","article-title":"Functional repair of CFTR by CRISPR\/Cas9 in intestinal stem cell organoids of cystic fibrosis patients","volume":"13","author":"Schwank","year":"2013","journal-title":"Cell Stem Cell"},{"issue":"Suppl 1","key":"10.1016\/j.jcf.2024.10.008_bib0045","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.jcf.2019.11.003","article-title":"The genetics and genomics of cystic fibrosis","volume":"19 Suppl 1","author":"Sharma","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2024.10.008_bib0046","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jcf.2018.05.004","article-title":"CFTR modulator theratyping: Current status, gaps and future directions","volume":"18","author":"Clancy","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.jcf.2024.10.008_bib0047","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1165\/rcmb.2019-0291OC","article-title":"Novel Correctors and Potentiators Enhance Translational Readthrough in CFTR Nonsense Mutations","volume":"64","author":"Mutyam","year":"2021","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"4","key":"10.1016\/j.jcf.2024.10.008_bib0048","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.molmed.2023.01.004","article-title":"Readthrough compounds for nonsense mutations: bridging the translational gap","volume":"29","author":"Spelier","year":"2023","journal-title":"Trends Mol Med"},{"issue":"9","key":"10.1016\/j.jcf.2024.10.008_bib0049","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1080\/15476286.2015.1068497","article-title":"Translational readthrough potential of natural termination codons in eucaryotes\u2013The impact of RNA sequence","volume":"12","author":"Dabrowski","year":"2015","journal-title":"RNA Biol"},{"issue":"5","key":"10.1016\/j.jcf.2024.10.008_bib0050","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3109\/10409238.2012.694846","article-title":"Suppression of premature termination codons as a therapeutic approach","volume":"47","author":"Keeling","year":"2012","journal-title":"Crit Rev Biochem Mol Biol"},{"issue":"1","key":"10.1016\/j.jcf.2024.10.008_bib0051","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s10020-018-0024-7","article-title":"Advances in therapeutic use of a drug-stimulated translational readthrough of premature termination codons","volume":"24","author":"Dabrowski","year":"2018","journal-title":"Mol Med"},{"issue":"2","key":"10.1016\/j.jcf.2024.10.008_bib0052","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/nar\/gkh201","article-title":"The major 5\u2032 determinant in stop codon read-through involves two adjacent adenines","volume":"32","author":"Tork","year":"2004","journal-title":"Nucleic Acids Res"},{"issue":"16","key":"10.1016\/j.jcf.2024.10.008_bib0053","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1093\/hmg\/ddx196","article-title":"Identification of the amino acids inserted during suppression of CFTR nonsense mutations and determination of their functional consequences","volume":"26","author":"Xue","year":"2017","journal-title":"Hum Mol Genet"},{"issue":"3","key":"10.1016\/j.jcf.2024.10.008_bib0054","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1002608","article-title":"Statistical analysis of readthrough levels for nonsense mutations in mammalian cells reveals a major determinant of response to gentamicin","volume":"8","author":"Floquet","year":"2012","journal-title":"PLoS Genet"},{"issue":"7","key":"10.1016\/j.jcf.2024.10.008_bib0055","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1164\/ajrccm.163.7.2004001","article-title":"Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis","volume":"163","author":"Clancy","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"10.1016\/j.jcf.2024.10.008_bib0056","doi-asserted-by":"crossref","first-page":"4612","DOI":"10.1128\/AAC.00965-08","article-title":"Interaction of aminoglycosides with human mitochondrial 12S rRNA carrying the deafness-associated mutation","volume":"53","author":"Qian","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.jcf.2024.10.008_bib0057","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jcf.2021.01.009","article-title":"Targeting G542X CFTR nonsense alleles with ELX-02 restores CFTR function in human-derived intestinal organoids","volume":"20","author":"Crawford","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.10.008_bib0058","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113886","article-title":"Nonsense codons suppression. An acute toxicity study of three optimized TRIDs in murine model, safety and tolerability evaluation","volume":"156","author":"Corrao","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.jcf.2024.10.008_bib0059","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1750-1172-7-58","article-title":"Rescue of nonsense mutations by amlexanox in human cells","volume":"7","author":"Gonzalez-Hilarion","year":"2012","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"10.1016\/j.jcf.2024.10.008_bib0060","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1164\/rccm.201601-0154OC","article-title":"Discovery of Clinically Approved Agents That Promote Suppression of Cystic Fibrosis Transmembrane Conductance Regulator Nonsense Mutations","volume":"194","author":"Mutyam","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.jcf.2024.10.008_bib0061","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1261\/rna.060236.116","article-title":"The nucleoside analog clitocine is a potent and efficacious readthrough agent","volume":"23","author":"Friesen","year":"2017","journal-title":"RNA"},{"issue":"4","key":"10.1016\/j.jcf.2024.10.008_bib0062","doi-asserted-by":"crossref","first-page":"e265","DOI":"10.1016\/S2352-3026(24)00006-1","article-title":"Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial","volume":"11","author":"Coppens","year":"2024","journal-title":"Lancet Haematol"},{"issue":"18","key":"10.1016\/j.jcf.2024.10.008_bib0063","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJMoa2309676","article-title":"Exagamglogene Autotemcel for Severe Sickle Cell Disease","volume":"390","author":"Frangoul","year":"2024","journal-title":"N Engl J Med"},{"issue":"6701","key":"10.1016\/j.jcf.2024.10.008_bib0064","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1126\/science.adk9428","article-title":"In vivo editing of lung stem cells for durable gene correction in mice","volume":"384","author":"Sun","year":"2024","journal-title":"Science"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324017971?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324017971?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T22:11:45Z","timestamp":1738275105000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199324017971"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1569199324017971"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2024.10.008","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A W1282X cystic fibrosis mouse allows the study of pharmacological and gene-editing therapeutics to restore CFTR function","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2024.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}